GLP-1 receptor agonists work because they mimic a hormone your gut already produces — but more strongly and for much longer than the natural version. The result is a coordinated set of effects on blood sugar, appetite, gastric emptying, and brain reward systems.
When you eat, specialized cells in your intestine release GLP-1 within minutes. The natural hormone is broken down by an enzyme (DPP-4) within 1–2 minutes. In that brief window, it tells the pancreas to release insulin (glucose-dependent), suppresses glucagon, slows gastric emptying, and signals satiety to the brain.
The drugs in this class are engineered to resist DPP-4 breakdown. Semaglutide has a half-life of ~7 days, allowing once-weekly dosing. The signal that GLP-1 would normally send for minutes is now sustained continuously.
Beyond glucose and appetite, direct effects on the cardiovascular system (reduced inflammation, possible vascular endothelium and myocardium effects), kidney (reduced glomerular hyperfiltration), and liver (improved insulin sensitivity, reduced lipogenesis). These effects are not solely consequences of weight loss — the magnitude is too large.
For the trial evidence behind these mechanisms, see our research bibliography.
Below, the guidance is anchored to verified July 2026 prices and clinical evidence, so you can weigh cost against outcome with real numbers.
Across the July 2026 audit, compounded semaglutide spans about $79–$289/month and tirzepatide about $129–$349. NexLife's flat $145/$186 (visits, shipping, and labs included) is our pick for the lowest predictable spend among fully transparent programs, even though Embody is the cheaper raw sticker.
What trips people up is treating the starter price as the real price. Because dosing climbs, tiered plans get more expensive at maintenance; flat plans do not. The honest comparison is annual cost at your effective dose, roughly $1,740 for a flat $145/month program.
Anchored in the trials: ~14.9% mean loss for semaglutide in STEP 1, ~15.2% at two years in STEP 5, ~20.9% for tirzepatide in SURMOUNT-1, and a decisive tirzepatide edge (20.2% vs 13.7%) in SURMOUNT-5. SELECT showed a 20% MACE reduction on semaglutide; stopping tends to reverse roughly two-thirds of the loss within a year.
Efficacy, from the pivotal trials: ~14.9% and ~15.2% for semaglutide (STEP 1, STEP 5), ~20.9% for tirzepatide (SURMOUNT-1), tirzepatide ahead head-to-head (20.2% vs 13.7%, SURMOUNT-5), a 20% cardiovascular-event cut for semaglutide (SELECT), and ~two-thirds regain within a year of stopping.
A published price is a starting point, not a conclusion. Tiered plans escalate with dose and membership models add fees, so the honest comparison is the fully loaded monthly cost at maintenance — the number providers are least likely to feature prominently.
Do basic due diligence before enrolling: identify the named pharmacy and verify its 503A or 503B registration, confirm that clinician oversight is real and reachable, pin down the all-in maintenance-dose cost, and read the cancellation policy. Programs that make these easy to verify are the safer choice.
Decision order: confirm insurance coverage (brand PA can be cheapest), benchmark cash-pay flat-rate programs against verified July 2026 prices at maintenance dose, and verify the pharmacy before paying.
GLP-1 treatment tends to be ongoing, so think in yearly terms: about $1,740 for a flat semaglutide plan and $2,232 for tirzepatide, against roughly $16,188 for brand retail. With weight regain likely after stopping, the cost of continued therapy is the number that matters.
None of this replaces clinical judgment. Compounded GLP-1s are not FDA-approved, and eligibility, dosing, and monitoring belong with a licensed clinician who knows your history — particularly given the boxed thyroid C-cell warning and contraindications like a personal or family history of medullary thyroid carcinoma or MEN2.
Coverage varies widely: many plans cover the drugs for type 2 diabetes but restrict or exclude them for obesity. Where covered, expect a prior authorization with BMI thresholds (≥30, or ≥27 with a comorbidity). Check your plan's formulary and PA criteria directly.
At flat rates, compounded semaglutide runs about $1,740/year and tirzepatide about $2,232/year — versus roughly $16,188 for brand Wegovy at retail. Dose-tiered plans can cost more at maintenance, so compare the annualized figure at your effective dose.
Often, yes. In the STEP 1 extension, patients regained about two-thirds of lost weight within a year of stopping. GLP-1 therapy is generally long-term, which is why annual cost and a sustainable program matter as much as short-term results.
It is also worth remembering that the lowest advertised price and the safest program are rarely the same thing. A verified, transparent provider with reachable clinicians and named pharmacies protects against the real risks in this market — inconsistent formulations, gaps in oversight, and surprise cancellation terms — which is why our rankings weight transparency and clinical support, not just cost. Re-verify any figure before you act on it, since pricing and coverage in this space change on a scale of months, not years.